TIGIT Antibody (TIGIT/3017)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-79793
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
ELISA, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array, Simple Western
Cited:
Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2c Kappa Clone # TIGIT/3017
Concentration
0.2 mg/ml
Product Specifications
Immunogen
Recombinant fragment (around aa 22-141) of human TIGIT protein (exact sequence is proprietary) (Uniprot: Q4951)
Localization
Cell Surface
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2c Kappa
Theoretical MW
26 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-79927)
Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
Scientific Data Images for TIGIT Antibody (TIGIT/3017)
Immunohistochemistry-Paraffin: TIGIT Antibody (TIGIT/3017) [NBP2-79793]
Immunohistochemistry-Paraffin: TIGIT Antibody (TIGIT/3017) [NBP2-79793] - Formalin-fixed, paraffin-embedded human Prostate Carcinoma stained with TIGIT Antibody (TIGIT/3017).Flow Cytometry: TIGIT Antibody (TIGIT/3017) [NBP2-79793]
Flow Cytometry: TIGIT Antibody (TIGIT/3017) [NBP2-79793] - Flow Cytometric Analysis of PFA-fixed MOLT4 cells. TIGIT Antibody (TIGIT/3017) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).Protein Array: TIGIT Antibody (TIGIT/3017) [NBP2-79793]
Protein Array: TIGIT Antibody (TIGIT/3017) [NBP2-79793] - Analysis of Protein Array containing more than 19,000 full-length human proteins using TIGIT Antibody (TIGIT/3017). Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (MAb) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProt(TM) array. Z-scores are described in units of standard deviations (SD's) above the mean value of all signals generated on that array. If targets on HuProt(TM) are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD's) between the Z-score. S-score therefore represents the relative target specificity of a MAb to its intended target. A MAb is considered to specific to its intended target, if the MAb has an S-score of at least 2.5.Applications for TIGIT Antibody (TIGIT/3017)
Application
Recommended Usage
Flow Cytometry
1-2 ug/million cells
Immunohistochemistry
1-2 ug/ml
Immunohistochemistry-Paraffin
1-2 ug/ml
Simple Western
reported by internal validation
Application Notes
ELISA: For coating, order antibody without BSA).
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
In Simple Western internal validation: NK cell lysate at 0.5 mg/ml, NSCLC cell lysate at 0.5 mg/ml as samples; separated by size; antibody dilution of 1:10; observed molecular weights at 46, 70, 102, 153, 224; matrix was 12-230 kDa; detected by Chemiluminescence.
Optimal dilution for a specific application should be determined.
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
In Simple Western internal validation: NK cell lysate at 0.5 mg/ml, NSCLC cell lysate at 0.5 mg/ml as samples; separated by size; antibody dilution of 1:10; observed molecular weights at 46, 70, 102, 153, 224; matrix was 12-230 kDa; detected by Chemiluminescence.
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10 mM PBS with 0.05% BSA
Preservative
0.05% Sodium Azide
Concentration
0.2 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: TIGIT
TIGIT is commonly used as a marker for T cell exhaustion and its expression correlates with disease progression. Furthermore, in viral infections including HIV and SIV, TIGIT serves as a target for immune restoration (6). In cancer detection, TIGIT is upregulated and coexpressed with programmed cell death protein 1 (PD-1) on the majority of circulating tumor antigen (TA)-specific CD8+ T cells (7). In addition to this, TIGIT can inhibit immune cells at multiple steps within the cancer immunity cycle. These include inhibiting NK cell effector function, suppressing dendritic cell costimulatory abilities, suppressing CD8+ T cell effector function by Tregs or polio virus receptor (PVR)-stimulated myeloid cells, and by directly inhibiting CD8+ T cells and preventing elimination of cancer cells (7).
References
1. Joller, N., & Kuchroo, V. K. (2017). Tim-3, Lag-3, and TIGIT. Current topics in microbiology and immunology, 410, 127-156. https://doi.org/10.1007/82_2017_62
2. Xu, Z., Jin, B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol 7, 11-19 (2010). https://doi.org/10.1038/cmi.2009.108
3. Uniprot(P86176
4. Khan, M., Arooj, S., & Wang, H. (2020). NK Cell-Based Immune Checkpoint Inhibition. Frontiers in immunology, 11, 167. https://doi.org/10.3389/fimmu.2020.00167
5. Harjunpaa, H., & Guillerey, C. (2020). TIGIT as an emerging immune checkpoint. Clinical and experimental immunology, 200(2), 108-119. https://doi.org/10.1111/cei.13407
6. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W., & Smyth, M. J. (2016). Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research, 22(21), 5183-5188. https://doi.org/10.1158/1078-0432.CCR-16-0933
7. Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017). TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends in immunology, 38(1), 20-28. https://doi.org/10.1016/j.it.2016.10.002
Long Name
T Cell Immunoreceptor with Ig and ITIM Domains
Alternate Names
VSIG9, VSTM3, WUCAM
Gene Symbol
Tigit
Additional TIGIT Products
Product Documents for TIGIT Antibody (TIGIT/3017)
Product Specific Notices for TIGIT Antibody (TIGIT/3017)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...